BUSM study finds older men more likely to lose the ability to orgasm due to gabapentin
2011-06-04
(Press-News.org) (Boston) - Boston University School of Medicine (BUSM) researchers have found that Gabapentin, (trade name Neurontin) a medication commonly used to treat neuropathic pain, seizures and biopolar disease in older and elderly patients, seems to have a higher incidence of anorgasmia, or failure to experience orgasm, than previously reported. This study appears in the current issue of the American Journal of Geriatric Pharmacotherapy.
Anticonvulsants are the fastest growing prescribed medication in the baby boomer generation. In patients 44-82 years old, anticonvulsants are more commonly prescribed than opioids. Gabapentin is a preferred medication, given its perceived benign side effects, typically limited to somnolence and dizziness that resolve with time.
Since its introduction in 1993, only 10 cases of anorgasmia have been reported, mostly in younger patients with an average age of 38 years. In this case study, three of the 11 patients who were over the age of 50 experienced anorgasmia. These male patients were 73, 76 and 78 years old. Interestingly, another case in a 59-year-old female was noted by colleagues at Tufts Medical Center.
"This is a much higher incidence than was reported in the original clinical trials. Gabapentin induced anorgasmia may be more common in older patients," according to lead author Michael D. Perloff, MD, PhD, an assistant professor neurology at BUSM. "Further, anorgasmia appears to be dose dependent. In all cases orgasm returned when Gabapentin was reduced or stopped."
The researcher recommends that clinicians should review the potential for anorgasmia with patients taking Gabapentin or discuss it at follow up. "If anorgasmia does occur, patients should be reassured that it is reversible and likely dose dependent," added Perloff.
INFORMATION:
END
ELSE PRESS RELEASES FROM THIS DATE:
2011-06-04
Almost all bacteria owe their structure to an outer cell wall that interacts closely with the supporting MreB protein inside the cell. As scientists at the Max Planck Institute for Biochemistry and at the French INRA now show, MreB molecules assemble into larger units, but not - as previously believed – into continuous helical structures. The circular movement of these units along the inside of the bacterial envelope is mediated by cell wall synthesis, which in turn requires the support of MreB. This mutual interaction may be a widespread phenomenon among bacteria and opens ...
2011-06-04
INDIANAPOLIS – A new research study investigates the challenges that pen and paper workarounds or computerized communication breakdowns pose to the use of electronic health records. Understanding these challenges may lead to improved coordination of care supported by health IT.
Focusing on referrals by primary care physicians to specialists and communications from the specialists back to the referring physician, "Paper Persistence, Workarounds, and Communication Breakdowns in Computerized Consultation Management" appears in the July 2011 issue of the International Journal ...
2011-06-04
In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate. Patients in the study, conducted at University Hospitals Case Medical Center, University of California, San Francisco and Columbia University, were found to have a median survival of 11 months compared to current three to five month survival.
"The findings are very ...
2011-06-04
Due to increasing international demand, MedWOW greatly expanded its operations by launching a Global Franchise Program. MedWOW's Franchise Program screens qualified medical equipment professionals throughout the world, in order to find the best representatives to join the MedWOW brand and offer the website's services in their defined territory.
The franchise program offers reputable key-players in the medical equipment industry the opportunity to expand their existing business, by giving them the rights to market MedWOW to end-users in their territories, including: ...
2011-06-04
Sexual pleasure among young adults (ages 18-26) is linked to healthy psychological and social development, according to a new study by researchers at the Johns Hopkins Bloomberg School of Public Health. The study is the first to use a representative population sample of heterosexuals to find a relationship between key developmental assets and sexual pleasure. The findings are published in the June 2011 issue of The Journal of Adolescent Health.
The research study examined data from 3,237 respondents ages 18 to 26 from the National Longitudinal Study of Adolescent Health, ...
2011-06-04
Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have demonstrated why certain immune cells chronically exposed to HIV shut down, and how they can be reactivated.
Healthy B cells have a balanced mix of surface proteins that the immune system can use, like the gas pedal and brake of a car, either to activate the cell or to damp down its activity. However, in people with long-term HIV infection who have not begun antiretroviral therapy, their B cells—responsible for producing anti-HIV antibodies—display ...
2011-06-04
Los Angeles, Calif., June 2, 2011—Researchers in the Keck School of Medicine of the University of Southern California (USC), together with scientists in Beijing, China, have discovered a chromosomal mutation responsible for a very rare condition in which people grow excess hair all over their bodies. Investigators hope the finding ultimately will lead to new treatments for this and less severe forms of excessive hair growth as well as baldness.
The study, "X-linked congenital hypertrichosis syndrome is associated with interchromosomal insertions mediated by a human-specific ...
2011-06-04
CHICAGO — Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted by The University of Texas MD Anderson Cancer Center.
MD Anderson's Phase I findings were presented today on the opening press program of the 47th Annual Meeting of the American Society of Clinical Oncology. Apostolia-Maria Tsimberidou, M.D., Ph.D., associate professor in MD Anderson's Department of Investigational Cancer Therapeutics, and the study's principal ...
2011-06-04
AURORA, Colo. (June 3, 2011) – A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
The patients taking crizotinib have anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) and the drug targets the gene ...
2011-06-04
(CHICAGO) – For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.
The findings of the study were published in the June 2 issue of New England Journal of Medicine. This marks the first vaccine study in the disease and one of the first in all cancers to show clinical benefit in a randomized Phase III clinical trial.
"This is the first time that a vaccine has shown benefit ...
LAST 30 PRESS RELEASES:
[Press-News.org] BUSM study finds older men more likely to lose the ability to orgasm due to gabapentin
